SNTI Senti Biosciences Holdings, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%
Returns
ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $22,000 | $0 |
| R&D expense | $37.59M | $34.36M |
| SG&A expense | $26.16M | $26.37M |
| Operating income | -$68.78M | -$61.04M |
| Income tax | $0 | $0 |
| Net income | -$61.44M | -$52.79M |
| EBITDA | -$65.14M | -$57.20M |
| EPS (basic) | -2.73 | -12.03 |
| EPS (diluted) | -2.73 | -12.03 |
| Weighted avg. shares (diluted) | 22.48M | 4.60M |
| Balance sheet | ||
| Cash & equivalents | $16.42M | $51.81M |
| Current assets | $23.27M | $58.96M |
| PP&E, net | $12.89M | $21.29M |
| Total assets | $51.22M | $97.84M |
| Current liabilities | $13.97M | $13.15M |
| Total liabilities | $45.63M | $47.09M |
| Shareholders' equity | $5.59M | $25.65M |
| Shares outstanding | 30.88M | 4.83M |
| Cash flow statement | ||
| Operating cash flow | -$43.44M | -$41.40M |
| Capital expenditure | $196,000 | $26,000 |
| Free cash flow | -$43.64M | -$41.42M |
| Investing cash flow | -$184,000 | $34,000 |
| Financing cash flow | $11.76M | $53.73M |
| Depreciation & amortization | $3.64M | $3.84M |
| Stock-based compensation | $5.71M | $1.75M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.